Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives
Pharmacy Practice · 12.03.2026 · 24 (1) · 1-13
DOI: 10.18549/pharmpract.2026.1.3337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Practice, online erschienen am 12.03.2026. Verfasst von Tasneem Al Anta und 9 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Anta, T. A., Shehadat, O. A., Taneera, J., Aleidi, S. M., Abuhelwa, A. A., Alzoubi, K. H., Semreen, M. H., Huneidi, W. E., Gharbieh, E. A., & Bustanji, Y. (2026). Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives. Pharmacy Practice, 24(1), 1-13. https://doi.org/10.18549/pharmpract.2026.1.3337
Vancouver
Anta TA, Shehadat OA, Taneera J, Aleidi SM, Abuhelwa AA, Alzoubi KH, et al. Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives. Pharmacy Practice. 2026;24(1):1-13. doi:10.18549/pharmpract.2026.1.3337
BibTeX
@article{Anta2026,
author = {Anta, Tasneem Al and Shehadat, Ola Al and Taneera, Jalal and Aleidi, Shereen M and Abuhelwa, Ahmad A and Alzoubi, Karem H and Semreen, Mohammad H and Huneidi, Waseem El and Gharbieh, Eman Abu and Bustanji, Yasser},
title = {Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives},
journal = {Pharmacy Practice},
year = {2026},
volume = {24},
number = {1},
pages = {1--13},
doi = {10.18549/pharmpract.2026.1.3337}
}
EUVIMED